NEWPORT NEWS, Va., Sept. 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that it has been awarded a contract from the U.S. Navy to start procurement of long-lead time materials (LLTM) for the construction of planned aircraft carrier CVN 82 at its Newport News Shipbuilding division.

The $336 million undefinitized contract award will initiate advanced procurement of propulsion plant materials critical to the future construction of CVN 82.

“Ordering the materials necessary to build the world’s mightiest aircraft carriers is a critical first step as we begin planning for CVN 82,” said Bryan Caccavale, NNS vice president of program management. “This contract sends an important demand signal to the thousands of suppliers across the nation who make up the aircraft carrier industrial base.”

CVN 82 will continue the legacy of highly capable nuclear-powered U.S. aircraft carriers.

DCS20-473-120

A photo accompanying this release is available at: http://hii.com/news/hii-is-awarded-long-lead-time-materials-contract-for-cvn-82/.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:

Todd Corillo
Todd.T.Corillo@HII-co.com
(757) 688-3220

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/995ce200-f9d6-440a-be87-da8cc1e255c9

PALOS VERDES ESTATES, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Malaga Financial Corporation (OTCIQ:MLGF) announced today the declaration of a cash dividend in the amount of 25 cents per share to shareholders of record on September 23, 2026. The dividend will be paid out on or about October 1, 2026. Randy C. Bowers, Chairman, President and CEO, remarked, “We are pleased to reward our loyal shareholders with this 25-cent quarterly dividend which represents a 4.45% annualized yield based on our most recent closing price of $22.46. We are grateful for the efforts of our colleagues which has positioned us to declare this 89th consecutive quarterly cash dividend.”

Malaga Bank, a subsidiary of Malaga Financial Corporation, is a full-service community bank headquartered on the Palos Verdes Peninsula with six offices located in the South Bay area of Los Angeles. For over eighteen years Malaga Bank has been consistently recommended by one of the nation’s leading independent bank rating and research firms, Bauer Financial Inc. Malaga Bank was awarded Bauer’s premier Top 5-Star rating for the 75th consecutive quarter as of June 2026. Since 1985, Malaga Bank has been delivering competitive consecutive banking services to residents and businesses of the South Bay, including real estate loan products custom-tailored to consumers and investors. As the largest community bank in the South Bay, Malaga is proud of its continuing tradition of relationship-based banking and legendary customer service. The Bank’s web site is located at www.malagabank.com.

Contact: Randy Bowers
Chairman, President and Chief Executive Officer
Malaga Financial Corporation
(310) 375-9000
rbowers@malagabank.com
   

  • FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
  • Newly approved Joenja doses are expected to be available in October

Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. With this approval, Joenja becomes the first FDA-approved treatment for children aged 4 to 11 years with APDS in the U.S. The newly approved Joenja doses are expected to be available to eligible pediatric patients in the U.S. in October through Pharming’s established specialty distribution network and patient-support infrastructure.

On July 30, Pharming also submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to11 years who weigh 13 kg to less than 27 kg.

“To give children living with APDS the best chance at a healthier future, early disease intervention is critical,” commented Eveline Wu, M.D., MSCR, Associate Professor of Pediatrics at the University of North Carolina at Chapel Hill. “Previously, our best approach for children aged 4 to 11 years with APDS was to provide an accurate diagnosis and a treatment plan to manage the symptoms of APDS. With the approval of Joenja for this pediatric population, we can now take that support even further to address the underlying pathway of disease, with the goal of reducing symptoms and preventing the irreversible complications that often arise with APDS.”

“APDS is not a disease that waits. It can affect important aspects of childhood, potentially impacting time in school, time with friends, and other activities of daily life. This approval is a meaningful step forward because it gives younger patients and their physicians another much-needed option earlier in the disease journey,” said Vanessa Tenembaum, CEO of the Jeffrey Modell Foundation, an international, non-profit, organization dedicated to helping individuals and family members affected by primary immunodeficiency disorders. “For families living with APDS, it means more than progress; it means renewed hope, greater possibility and a clearer path forward.”

APDS typically manifests in early childhood and is characterized by significant immune dysregulation and recurrent sinopulmonary infections, which over time can lead to permanent lung damage and other serious complications. For children living with APDS, the burden can extend beyond clinical symptoms. Recurrent infections, medical appointments and treatment demands may disrupt school attendance, learning and social development, adding to the daily impact on patients and families.

“Today’s approval marks an important achievement in our efforts to expand the availability of Joenja to more individuals living with APDS. We are grateful to the FDA, trial participants, caregivers, investigators, healthcare providers and the APDS community whose partnership helped make this milestone possible,” said Leverne Marsh, Chief Commercial Officer of Pharming. “Our immediate priority is to support physicians and families in navigating the access pathway so treatment can start as quickly and responsibly as possible.”

Joenja received approval from the U.S. FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. Today’s approval is supported by data from a multinational, open-label, single-arm Phase III study in children aged 4 to 11 years with APDS. The study demonstrated improvements over 12 weeks in two clinically relevant hallmarks of the condition, reduced lymphadenopathy and increased naïve B cells, together indicating an improvement in the underlying immune defect. The safety profile was consistent with prior Joenja experience; all treatment emergent adverse events were mild to moderate in nature, and no drug related serious adverse events were observed.

US Important Safety Information for Joenja® (leniolisib)

INDICATIONS AND USAGE
Joenja® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.

IMPORTANT SAFETY INFORMATION
Verify pregnancy status in females of reproductive potential prior to initiating treatment with Joenja.

Joenja may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with Joenja and for 1 week after the last dose. Additionally, advise women not to breastfeed during treatment with Joenja and for 1 week after the last dose.

Live, attenuated vaccinations may be less effective if administered during Joenja treatment.

Joenja may cause hypersensitivity reaction(s), including anaphylaxis. Advise patients to discontinue Joenja and to seek immediate medical attention if they develop any signs and symptoms of serious allergic reactions.

Use of Joenja in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients under 4 years of age or weighing less than 27 kg.

Avoid co-administration of Joenja with other medications known to be strong CYP3A4 inhibitors, strong or moderate CYP3A4 inducers, or BCRP, OATP1B1, and OATP1B3 substrates.

Most common adverse reaction (incidence >10%):

  • Adult and pediatric patients 12 years of age and older: headache, sinusitis, atopic dermatitis, and weight gain.
  • Pediatric patients 4 to <12 years of age who weigh 27 kg or greater: abdominal pain, cough, and respiratory tract infection.

Seven (33%) patients 12 years and older (n=21) and 5 (63%) patients 4 to 12 years of age and weighing more than 27 kg or greater (n=8) developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL after receiving Joenja. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing Joenja, please read the full Prescribing Information.

Joenja is available in 40 mg, 50 mg, and 70 mg tablets.

Based on PI Approved: 09/2026

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) 
APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation1,2,3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.8 

About Joenja®
Joenja® (leniolisib) is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved as the first and only treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the U.S., U.K., Australia, Israel, Canada and the European Union in adult and pediatric patients 12 years of age and older and in Japan for patients 4 years of age and older. Joenja® inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration.9,10   
Leniolisib is currently under regulatory review for the treatment of APDS in Canada and several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.  

About Pharming
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biotechnology company that develops and commercializes innovative medicines for people living with rare immune and genetic diseases.

We combine specialized scientific, medical, regulatory and commercial expertise to advance a focused portfolio of approved medicines and development programs that address significant unmet medical needs. Guided by insights from patients and the wider rare disease community, we are dedicated to delivering innovative therapies for some of the most challenging rare diseases. 

Pharming is headquartered in Leiden, the Netherlands, with operations in the United States and Europe. 

For more information, visit www.pharming.com and follow us on LinkedIn. 

Forward-looking Statements
This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2025 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References 

  1. FDA. Priority Review. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review Accessed October 2025.
  2. Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.
  3. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
  4. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.
  5. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
  6. Maccari ME, et al. Front Immunol. 2018;9:543.
  7. Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.
  8. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.
  9. Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.
  10. Rao VK, et al.  J Allergy Clin Immunol 2024;153:265-74.

For further public information, contact:
Pharming
Michael Levitan, VP Investor Relations & Capital Markets
T: +1 (908) 705 1696
E: investor@pharming.com

Saskia Mehring, Head of Corporate Communications
T: +31 6 28 32 60 41
E: media.relations@pharming.com

Media Relations
Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming)
E:  JDeutsch@lyraadvisory.com

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

Company completes 104.8-ton bulk-sampling program at Skaergaard; advances geological mapping and environmental baseline studies at Sarfartoq

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Sling operation for the opening of the Sarfartoq exploration camp.
Sling operation for the opening of the Sarfartoq exploration camp.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Blasted material being hammered into smaller fragments and loaded in bulk bags.
Blasted material being hammered into smaller fragments and loaded in bulk bags.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

WSP Denmark consultant carrying out environmental base line study work near the ST1 REE mineralized zone at Sarfartoq.
WSP Denmark consultant carrying out environmental base line study work near the ST1 REE mineralized zone at Sarfartoq.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Bulk bags slung to lay-down area at Uttendal Sund at Skaergaard with anchored support vessel Argus in the background.
Bulk bags slung to lay-down area at Uttendal Sund at Skaergaard with anchored support vessel Argus in the background.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Newly installed weather station at Sarfartoq – part of the second year of environmental baseline study. Exploration camp at Sarfartoq in the background.
Newly installed weather station at Sarfartoq – part of the second year of environmental baseline study. Exploration camp at Sarfartoq in the background.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Blasting in one of the gold mineralized zones within the Skaergaard Intrusion. The blasted material will be collected and used for metallurgical and processing flowsheet purposes.
Blasting in one of the gold mineralized zones within the Skaergaard Intrusion. The blasted material will be collected and used for metallurgical and processing flowsheet purposes.

Greenland Mines Provides Progress Update on 2026 Field Programs at Skaergaard and Sarfartoq

Holes loaded and ready for blasting at Skaergaard 2026.
Holes loaded and ready for blasting at Skaergaard 2026.

CHARLOTTE, N.C., Sept. 11, 2026 (GLOBE NEWSWIRE) — via IBN – Greenland Mines Ltd (Nasdaq: GRML) (“Greenland Mines” or the “Company”) today provided an update on the progress of its 2026 field programs at the Skaergaard palladium-platinum-gold project in East Greenland and the Sarfartoq rare earth element project in West Greenland.

Bo Møller Stensgaard, President of Greenland Mines, commented:
“Our teams have delivered an outstanding field season at both projects. At Skaergaard, we set out to collect representative bulk material from three key horizons and ended up completing seven bulk-sample sites, giving GTK Mintec and our other metallurgical consultants substantially more material and more variability data than originally planned.

“At Sarfartoq, only weeks after closing the acquisition and announcing an Initial Assessment that demonstrated a high-case pre-tax net present value of approximately US$2.05 billion and a pre-tax internal rate of return of 118.6%, we already have boots on the ground running both structural mapping and the second year of environmental baseline studies.

“This is exactly the kind of execution and pace we committed to our shareholders, and it positions both projects well ahead of their next technical milestones.”

Skaergaard: Bulk-Sampling Program Completed, Exceeding Plan

Greenland Mines has completed its 2026 bulk-sample blasting program at Skaergaard, collecting a total of 104.8 tons of mineralized and host material from seven sites — more sites than originally planned for the season. All bulk samples were weighed in the field while being sling-loaded by helicopter to a central lay-down area, with final confirmed weights to follow in the next phase of test work.

The program’s three major bulk-sample sites, yielding approximately 30.4, 28.3 and 30.6 tons of material, were located at the toe area in front of Forbindelsesgletscher, on the eastern shore of Uttentaldal Sund. These sites targeted, respectively, the modelled Palladium-Platinum-dominated mineralized Horizon 0, the Gold-dominated mineralized Horizon 3, and the interstitial vanadium-bearing titanomagnetite (VTM) horizons within the Skaergaard gabbro sequence.

Horizon 0 and Horizon 3 form part of the resource-defining horizon framework established for the Skaergaard Mineral Resource Estimate, with Horizon 0 hosting the Company’s palladium-dominant “floor” mineralization and Horizon 3 hosting more gold-enriched material higher in the sequence. The VTM horizons occur as laterally continuous, oxide-bearing intervals interlayered with the precious-metal horizons, reflecting the intrusion’s distinctive combination of a fine-grained, alloy-hosted precious metals system overlying a coarser-grained iron-titanium-vanadium oxide system.

Site selection for all three major bulk samples was based on detailed geological mapping and the modelled surface outcrop expressions of the gold- and palladium-platinum-dominated horizons and the VTM intervals, cross-checked against historical geochemical assay data.

This included non-SK-1300-compliant historical assay data from three approximately 800-kilogram mini-bulk samples collected by blasting in 2003 from the same general area — one from the palladium-dominated horizon, returning historical assays of up to 4.34 g/t palladium and up to 0.54 g/t gold, and two from the gold-dominated horizon, returning historical assays of approximately 3.3 g/t gold and up to 0.5 g/t palladium — together with non-SK-1300-compliant historical channel-sample assay data across the horizons, with the most recent channel data dating from 2021. These historical figures are provided for geological context only, are non-S-K 1300 compliant, and were not relied upon in the Company’s current Mineral Resource Estimate.

In addition to the three major bulk-sample sites, four medium-sized bulk samples were collected from four further sites. These include two samples from the assumed outcropping, gold-dominated Horizon 5, weighing approximately 7.3 tons and 3.9 tons respectively, as well as two samples totaling approximately 4.3 tons from the southwest of the intrusion, representing the assumed outcropping palladium-platinum-dominated Horizon 0. These samples were collected to support variability studies, an essential step toward establishing a well-defined and stable metallurgical processing flowsheet.

As with the major sites, selection of these medium-sized sample locations was based on detailed mapping and modelled surface outcrop expressions, supported by historical channel-sample assay data across the horizons, with the most recent data from 2021.

The blasting program was carried out by an experienced blast crew from Greenlandic contractor Permagreen, working alongside Greenland Mines’ own geological and technical team, which also participated in collecting the blasted material into large heli-portable bulk bags. The bulk sample bags will be shipped later this season to GTK Mintec in Finland, where they will be used for large-scale test work and pilot-scale test work aimed at establishing an efficient and robust processing route for the gold-, palladium- and platinum-mineralized and VTM-bearing material at Skaergaard.

All bulk-sample sites were covered by new channel sampling for later reference assay work and also covered by detailed drone-based LiDAR digital elevation surveys and photography, enabling the Company to precisely map the volumes of material removed at each site.

Independent topic specialists in mine engineering, infrastructure planning, processing, and tailings and waste-rock management were also on site over recent weeks, working alongside the Greenland Mines team to assess site conditions, collect topic-specific data, and plan the next phase of technical work at Skaergaard.

Separately, the Company has successfully completed its ground-penetrating radar survey program at Skaergaard, generating detailed measurements of surface cover thickness and characteristics that will support ongoing infrastructure and mine engineering studies.


Sarfartoq: Camp Opened, Structural Mapping Underway, Second Year of Environmental Baseline Studies Completed

At Sarfartoq, Greenland Mines has opened and fully manned its exploration camp for the 2026 field season, marking the first full field program since the Company closed its acquisition of the project on September 1, 2026.

This work builds directly on the compelling project economics established by the Company’s Initial Assessment and closing of the Sarfartoq acquisition earlier this month, under which the ST1 deposit alone supports a high-case pre-tax net present value of approximately US$2.05 billion and a pre-tax internal rate of return of 118.6%, including Indicated and Inferred Mineral Resources, based on a nine-year mine life processing 12.2 million tons of material at a delivered head grade of 1.32% TREO. At 2025 consumption levels, Sarfartoq’s planned annual NdPr oxide production would represent approximately 34% of all NdPr oxide refined outside China, in every one of the Project’s nine scheduled operating years — underscoring why the Company is moving immediately from acquisition into the resource-growth and permitting work described below.

A consultancy team from WSP Denmark has been on site at Sarfartoq since early September conducting the second year of environmental baseline studies at Sarfartoq, building on the first year of baseline work completed in 2023. With this second year of fieldwork, Sarfartoq now has baseline data spanning the minimum two-year period required by Greenland’s Environmental Agency for Mineral Resource Activities.

The 2026 program includes terrestrial sampling of lichens across fifteen stations, including three reference stations, to characterize background metal levels; freshwater sampling at five stations across the Paradise Valley and Robinson Valley catchments, including collection of Arctic char; marine intertidal sampling of seaweed, mussels and sculpin near the planned port facility; servicing of the water-flow monitoring station installed in 2023 – which was found to be in good condition and with a data record from the last three years; and general botanical, mammal and bird surveys across the license area. All sampling is being conducted in accordance with protocols developed by the Danish Centre for Environment and Energy for the Greenland mineral resources environmental sample bank, and the work is being carried out with specific accommodation for protected zones in the area, including the Arnnangarnup Qoorua valley and adjacent goose moulting and breeding grounds.

Separately, a geological and structural mapping team led by consulting structural geologist Jeroen van Gool — who brings an extensive personal research history in the Sarfartoq area from previous work in Greenland — is now on site for a three-week program running through late September. The team includes consultants and experienced Greenland-focused geologists together with geology students from the University of Copenhagen.

The program is focused on producing a coherent, detailed geological and structural map of the northern part of the Sarfartoq license, an area that hosts both the prime ST1 resource zone and several additional rare earth exploration targets. The team is collecting rock samples for geochemical analysis, including portable XRF measurements in the field and laboratory whole-rock analysis, to help refine understanding of the grade and extent of known mineralization and to test for new, previously unrecognized occurrences of economic interest across the license.

The program also incorporates hand-held geophysical instrumentation and drone-based topographic mapping to generate detailed orthophotos and a digital elevation model of the mapped area, adding a further layer of high-resolution structural context ahead of the next phase of resource expansion work at Sarfartoq.

About Greenland Mines Ltd

Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and select midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.

Forward-Looking Statements
 This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the Company’s field programs, exploration and metallurgical testwork plans, environmental permitting pathway, and expected timing of future technical studies at Skaergaard and Sarfartoq. These statements are based on current expectations and are subject to risks and uncertainties, including exploration, permitting, weather-related, logistical and financing risks. Field-measured tonnages referenced in this release are preliminary and subject to confirmation. Historical assay data referenced in this release relating to 2003 mini-bulk samples and historical channel sampling are historical in nature, have not been verified by a Qualified Person under SK-1300 or S-K 1300, and should not be relied upon as indicative of current or future mineral resources or reserves. The Initial Assessment for Sarfartoq referenced in this release is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have modifying factors applied to them that would enable them to be categorized as Mineral Reserves; there is no certainty that the results of the Initial Assessment will be realized, and no Mineral Reserves have been estimated for the Sarfartoq Project. Readers should refer to the Company’s SEC filings and technical report summaries for complete disclosure and risk factors.

Investor Contact and Corporate Communications:

ir@greenlandmines.com

Website: www.greenlandmines.com

Corporate Communications:

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Attachments

NORTH LIBERTY, Iowa, Sept. 11, 2026 (GLOBE NEWSWIRE) — Heartland Express, Inc. (Nasdaq: HTLD) announced that Chris Strain, Chief Financial Officer, will participate at the Morgan Stanley 14th Annual Laguna Conference on Tuesday, September 15, 2026.

Heartland Express is an irregular route truckload carrier based in North Liberty, Iowa serving customers with shipping lanes throughout the United States and Mexico. Heartland focuses primarily on regional freight, offering shippers industry leading on-time service so they can achieve their strategic goals for their customers. More information about Heartland Express can be found on the company website at www.heartlandexpress.com.

Information presented at the conference may contain forward-looking statements made by Heartland. Forward-looking statements are based upon the current beliefs and expectations of Heartland’s management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Accordingly, actual results may differ from those set forth in the forward-looking statements. Readers should review and consider the factors that may affect future results and other disclosures by Heartland in its press releases, stockholder reports, Annual Report on Form 10-K, and other filings with the Securities and Exchange Commission. Heartland disclaims any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

Contact:

Heartland Express, Inc.

Mike Gerdin, Chief Executive Officer
Chris Strain, Chief Financial Officer

319-645-7060

Transparency notification by
BNP Paribas Asset Management Holding
and BNP Paribas Cardif

In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by BNP Paribas Asset Management Holding and BNP Paribas Cardif that they had crossed above the legal threshold of 3% of direct voting rights on 4 September 2026.

The total holding of direct voting rights and equivalent financial instruments of BNP Paribas Asset Management Holding and BNP Paribas Cardif stood at 3.06% on 4 September 2026.

Summary of the move:

Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total
4 September 2026 8 September 2026 3.06% 0.00% 3.06%


Notification from BNP Paribas Asset Management Holding and BNP Paribas Cardif:

The notification contains the following information:

  • Date of notification: 8 September 2026
  • Date on which the threshold was crossed: 4 September 2026
  • Threshold of direct voting rights crossed upwards: 3%
  • Notification by: BNP Paribas Asset Management Holding and BNP Paribas Cardif
  • Denominator: 246,400,000
  • Reason for notification: Acquisition or disposal of voting securities or voting rights

Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held are available on the Transparency Declaration section of Umicore’s website.

About Umicore

Umicore is a global advanced materials and recycling Group. Leveraging decades of expertise in materials science, metallurgy, chemistry, and metals management, Umicore transforms precious and critical metals into functional technologies that enable everyday applications. Its unique circular business model ensures that these critical elements are continuously refined and recycled, to be reintegrated in new applications.

Umicore’s four Business Groups – Catalysis, Recycling, Specialty Materials and Battery Materials Solutions – offer materials and solutions addressing resource scarcity and the growing need for functional materials for clean technologies, clean mobility and a connected world. Through tailored and cutting-edge products and processes they drive innovation and sustainability.

Umicore generates the majority of its revenues from, and focuses most of its R&D efforts on, clean mobility and recycling. Its overriding goal of sustainable value creation is rooted in developing, producing and recycling materials for a better life.

Umicore’s industrial, commercial and R&D activities, with more than 11,000 employees, are located across the world to best serve its global customer base. Group revenues (excluding metal) reached € 1.9 billion (turnover of € 13.9 billion) in the first half of 2026.

For more information

Caroline Kerremans  +32 2 227 72 21  caroline.kerremans@umicore.com
Bart Heylen +32 2 227 73 09  bart.heylen@umicore.com

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi
a French société anonyme with a registered share capital of €2,415,546,786
Registered office : 46, avenue de la Grande Armée – 75017 Paris – France
Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  

Total number of
issued shares

 

Number of real
voting rights
(excluding treasury shares)
Theoretical number of
voting rights
(including treasury shares)*
August 31, 2026  

1,207,773,393

 

1,336,151,933

 

1,343,318,995

* Pursuant to Article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi:

https://www.sanofi.com/en/investors/sanofi-share-and-adrs/shares-structure-vote

Investor Relations Department
e-mail: investor.relations@sanofi.com

 

 

Attachment

11 September 2026

PayPoint plc (the “Company”)

Notification of transactions by Persons Discharging Managerial Responsibilities (“PDMRs”)

Vesting of 2023 Restricted Share Plan Awards

The Company announces that, in accordance with the rules of the PayPoint Restricted Share Plan (“RSP”), the conditional share awards granted on 8 September 2023 to the PDMRs listed below vested on 8 September 2026, having achieved the required performance conditions.

PDMR Number of shares granted

Dividend equivalent shares accrued Gross number of shares vested Number of shares cash settled to cover taxes due1 Net vested shares2 Number of shares sold
Nicholas Wiles 67,079 15,072 82,151 38,610 43,541 0
David Robert Harding 35,874 8,058 43,932 20,648 23,284 0
Katy Wilde 8,002 1,794 9,796 4,604 5,192 5,192
Josephine Toolan 6,950 1,554 8,504 3,996 4,508 0
Christopher Paul 4,170 930 5,100 2,397 2,703 2,703
Simon Coles 8,968 2,007 10,975 5,158 5,817 0
Anthony Sappor 3,766 839 4,605 2,164 2,441 0
Ben Ford 8,168 1,830 9,998 4,699 5,299 5,299
Mark Latham 7,847 1,760 9,607 4,515 5,092 5,092
Tanya Murphy 7,837 1,755 9,592 4,508 5,084 0
Stephen O’Neill 3,901 871 4,772 2,242 2,530 2,530
Julian Coghlan 9,865 2,213 12,078 5,676 6,402 6,402
John Lynch 2,392 529 2,921 1,226 1,695 0

1 Shares were cash settled to cover income tax and national insurance contributions due on vesting. The share price on release was £6.02485 per share.
2 Satisfied from the PayPoint Employee’s Share Trust.

The Notification of Dealing Forms can be found below.

This Notification is made in accordance with the requirements of the UK Market Abuse Regulation.

Enquiries:

PayPoint Plc           
Sophie Line, on behalf of Indigo Corporate Secretary Limited, Company Secretary
+44 (0)7927132060

Steve O’Neill, Chief Marketing and Corporate Affairs Officer
+44 (0)7919488066

LEI: 5493004YKWI8U0GDD138

https://www.paypointbusiness.com/corporate

1. Details of the person discharging managerial responsibilities/person closely associated
a)

Name

  1. Nicholas Wiles
  2. David Robert Harding
  3. Katy Wilde
  4. Josephine Toolan
  5. Christopher Paul
  6. Simon Coles
  7. Anthony Sappor
  8. Ben Ford
  9. Mark Latham
  10. Tanya Murphy
  11. Stephen O’Neill
  12. Julian Coghlan
  13. John Lynch
 
2. Reason for the notification
a) Position/status
  1. Chief Executive Officer
  2. Chief Finance Officer
  3. PDMR
  4. PDMR
  5. PDMR
  6. PDMR
  7. PDMR
  8. PDMR
  9. PDMR
  10. PDMR
  11. PDMR
  12. PDMR
  13. PDMR
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint Plc
b) LEI 5493004YKWI8U0GDD138
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.3611 pence each

ISIN: GB00BVMTNR93

b) Nature of the transaction Vesting of conditional share awards under the Company’s Restricted Share Plan.
c) Price(s) and volume(s) Price Volume(s)
    1.  £6.02485 82,151
    2.  £6.02485 43,932
    3.  £6.02485 9,796
    4.  £6.02485 8,504
    5.  £6.02485 5,100
    6.  £6.02485 10,975
    7.  £6.02485 4,605
    8.  £6.02485 9,998
    9.  £6.02485 9,607
    10. £6.02485 9,592
    11. £6.02485 4,772
    12. £6.02485 12,078
    13. £6.02485 2,921
       
d) Aggregated information
  1. £494,947.45
  2. £264,683.71
  3. £59,019.43
  4. £51,235.32
  5. £30,726.74
  6. £66,122.73
  7. £27,744.43
  8. £60,236.45
  9. £57,880.73
  10. £57,790.36
  11. £28,750.58
  12. £72,768.14
  13. 17,598.59
e) Date of the transaction 8 September 2026
f) Place of the transaction Outside a trading venue

1. Details of the person discharging managerial responsibilities/person closely associated
a)

Name

  1. Katy Wilde
  2. Christopher Paul
  3. Ben Ford
  4. Mark Latham
  5. Stephen O’Neill
  6. Julian Coghlan
 
2. Reason for the notification
a) Position/status
  1. PDMR
  2. PDMR
  3. PDMR
  4. PDMR
  5. PDMR
  6. PDMR
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name PayPoint Plc
b) LEI 5493004YKWI8U0GDD138
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.3611 pence each

ISIN: GB00BVMTNR93

b) Nature of the transaction Sale of net vested shares awarded under the Company’s Restricted Share Plan.
c) Price(s) and volume(s) Price Volume(s)
1. £6.02485 5,192
2. £6.02485 2,703
3. £6.02485 5,299
4. £6.02485 5,092
5. £6.02485 2,530
6. £6.02485 6,402
   
d) Aggregated information
  1. £31,281.02
  2. £16,285.17
  3. £31,925.68
  4. £30,678.54
  5. £15,242.87
  6. £38,571.09
 
e) Date of the transaction 8 September 2026
f) Place of the transaction London Stock Exchange, Main Market (XLON)

HONG KONG, Sept. 11, 2026 (GLOBE NEWSWIRE) — The 11th Belt and Road Summit, co-hosted by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), was officially opened on 9 September. As an official partner of the summit, CICC (China International Capital Corporation Limited) once again took part in the event. Wang Shuguang, President of CICC, was invited to attend the summit and deliver opening remarks at a thematic session.

Under the theme “Advancing High-quality Development • Embarking on a New Journey”, this year’s summit brought together government officials, business leaders, finance and investment experts, technology enterprise representatives and economists from countries and regions participating in the Belt and Road Initiative. Attendees reviewed the substantial progress delivered under the Initiative, exchanged insights on practical multilateral cooperation, and mapped out a vision for mutually beneficial development. John Lee Ka-chiu, Chief Executive of the HKSAR, and Frederick Ma Si-hang, Chairman of the HKTDC, attended the opening ceremony and delivered addresses.

At the thematic session entitled “High-Quality Belt and Road Cooperation: Connecting Markets, Creating Opportunities”, Wang Shuguang stated in his opening remarks that with its unique edge of “backed by the motherland and connected to the world”, Hong Kong stands as a pivotal platform for high-quality Belt and Road development. As a hub linking the Chinese mainland to global capital markets, Hong Kong continues to fulfill its unparalleled role as a “super connector”, bridging the mainland’s industrial strengths with global capital resources. This distinctive positioning was strongly validated in the capital markets: in 2025, Hong Kong’s IPO market reclaimed the No. 1 spot globally for fundraising after a six-year hiatus, raising over HK$ 286.9 billion — a strong testament to the solid fundamentals and vibrant dynamism of Hong Kong as an international financial hub.

He noted that over the past two years, CICC has sponsored the Hong Kong listings of leading hard technology enterprises including CATL and Zhongji Innolight, attracting participation from major long-term investors such as sovereign wealth funds across the Middle East and Europe. This fully underscores the appeal of China’s high-quality enterprises and global market confidence in China’s high-quality economic development. Meanwhile, CICC has continued to deepen its presence in Belt and Road cross-border financial services, having acted as lead underwriter for its inaugural Panda Bond issuances in multiple markets including Pakistan and Kazakhstan. The Jiaxin International Resources Investment Limited listing, sponsored by CICC in 2025, marked the world’s first simultaneous dual primary listing on both The Stock Exchange of Hong Kong Limited (HKEX) and the Astana International Exchange (AIX) of Kazakhstan, setting a new benchmark for cross-border financial cooperation under the Belt and Road development.

During the forum, China International Capital Corporation (CICC) signed memorandum of understanding with the Ministry of Finance and related enterprises of Laos, as well as with the National Bank for Foreign Economic Activity of Uzbekistan. The parties will deepen cooperation in areas such as cross-border investment and financing, financial product innovation, and the issuance of RMB-denominated bonds. This series of agreements marks an important step in the company’s expansion into Southeast Asian and Central Asian markets, and in its efforts to support the Belt and Road Initiative. Guided by its core mission of “Chinese Roots, International Reach”, CICC is committed to delivering premium comprehensive financial services to high-quality enterprises, institutions and investors worldwide. Looking ahead, we will continue to leverage our professional expertise, work alongside global clients and partners to seize new opportunities in high-quality Belt and Road development, while contributing to cross-border capital flows, deeper regional economic cooperation, and stronger connectivity between the capital markets of the Chinese mainland and Hong Kong.

CONTACT: For enquiries, please contact CICC PR team: 
pr_overseas@cicc.com.cn

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.